ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Falls 4.7% - Time to Sell?

Key Points

• CHRN shares fell 4.7% to $15.30 in midday trading, with volume plunging 99% below the average session level.
• Analyst sentiment is mixed: Compass Point initiated coverage with a Buy rating and a $25 target, while Northland Securities set an Outperform rating and $32 target. The consensus rating remains Hold, with a $21 price target.
• The company reported a quarterly loss of $0.29 per share on $41.48 million in revenue, alongside a negative net margin of 135.66% and negative return on equity of 66.16%; analysts expect a full-year loss of $0.39 per share.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) shares fell 4.7% during mid-day trading on Monday. The stock traded as low as $15.15 and last traded at $15.30. Approximately 3,335 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 227,400 shares. The stock had previously closed at $16.05.

Analysts Set New Price Targets

CHRN has been the subject of a number of recent analyst reports. Northland Securities assumed coverage on shares of ChronoScale Corporation Common Stock in a research note on Friday, September 18th. They issued an "outperform" rating and a $32.00 target price for the company. Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a research report on Friday, October 9th. Finally, Compass Point began coverage on shares of ChronoScale Corporation Common Stock in a research note on Friday. They issued a "buy" rating and a $25.00 price target on the stock. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $21.00.

ChronoScale Corporation Common Stock Stock Up 3.2%

The firm has a 50-day moving average of $19.78 and a two-hundred day moving average of $18.23. The company has a quick ratio of 0.30, a current ratio of 0.30 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $2.27 billion, a PE ratio of -2.89 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. The company had revenue of $41.48 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 66.16%. Equities research analysts predict that ChronoScale Corporation Common Stock will post -0.39 earnings per share for the current fiscal year.

Institutional Trading of ChronoScale Corporation Common Stock

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc grew its holdings in ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,338 shares of the company's stock after acquiring an additional 1,195 shares during the period. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 6.42% of the company's stock.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.